A distinguished pharmaceutical executive with almost 30 years of industry experience, John Klein serves as the chairman of Cambridge Therapeutics in Alpine, NJ. In addition to guiding the business development of Cambridge Therapeutics, John Klein actively follows NJ news in the areas of health care policy.
New Jersey Governor Phil Murphy recently appointed Judith Persichilli to serve as the new head of the NJ Department of Health beginning in July 2019. A well-known hospital executive and registered nurse, Ms. Persichilli replaces Dr. Shereef Elnahal, who took a chief executive position with Newark’s University Hospital. The appointment awaits confirmation from the state’s Senate.
A resident of Pennington, Ms. Persichilli formerly served as the director of Trinity Health before spending much of 2018 at University Hospital, where she worked to study and reform the struggling facility. Nursing and hospital leaders, as well as the New Jersey Health Care Quality Institute that Ms. Persichilli helped establish, applauded her appointment. She is known for not only her experience as a clinician and administrative expertise in the health care sector, but also her strong leadership skills.
Executive John Klein serves as the chairman of Cambridge Therapeutics, a pharmaceutical company based in Teaneck, New Jersey. To inform the decisions he makes at Cambridge Therapeutics, John Klein follows healthcare-related news in New Jersey.
In May, an Assembly committee in the Garden State unanimously approved a new proposal that addresses loneliness and social isolation among seniors and other at-risk individuals in the Garden State, such as veterans and people with disabilities and mental illnesses. This decision comes after the creation of a task force by Democratic legislators to assess the frequency of social isolation among these groups.
A month prior, the National Institute on Aging published research results stating 28 percent of elderly adults in the United States live alone. While this doesn’t mean these individuals are lonely, it was noted that social isolation can increase the risk of heart disease, high blood pressure, and cognitive decline. Another study from the AARP Foundation also concluded that one in three people in the US over the age of 45 feel lonely.
The Assembly’s proposal to address this issue encourages the creation of new state programs for reducing the occurrence of loneliness. Their design would be based on common risk factors and loneliness levels among different groups as gauged by the task force on social isolation and loneliness. Further, the proposal calls for the panel to evaluate current state and local efforts to tackle the impact of social isolation.
A successful executive who earned a spot on Forbes’ list of the Top 100 CEOs, John Klein serves as the chairman of Cambridge Therapeutics in Teaneck, New Jersey. Credited with securing Food and Drug Administration approval for more than 300 generic drugs, Cambridge Therapeutics Chairman John Klein is interested in health developments in the state of New Jersey.
In May, New Jersey health officials announced that 22 people in the state had been diagnosed with Legionnaires’ disease, five of whom had died from the disease. The nearly two dozen cases occurred between March 8 and May 13 among people who reside in or visited Union County.
Legionnaires’ disease is contracted by breathing in small water droplets containing the bacteria Legionella, which is sometimes found in the air conditioning units for large buildings, decorative fountains, plumbing systems, or cooling misters. The disease cannot be contracted through drinking water or home air conditioning units, said New Jersey Health Department officials. As the investigation into the outbreak continues, officials assured residents and visitors to Union County that the risk of contracting the disease is small.
The chairman of Cambridge Therapeutics, John Klein possesses nearly 30 years of experience as an executive in the health and pharmaceutical industries. In tandem with his responsibilities at Cambridge Therapeutics, John Klein actively follows new developments in the fields of health, pharmaceuticals, and public policy.
Released in May 2019, the most recent Leapfrog Hospital Safety report card ranks New Jersey hospitals sixth in the nation for prioritizing safety. Rankings are based on the efficacy of hospitals’ policies to prevent medical mistakes and protect patients from avoidable problems, like infections, falls, or receiving the wrong treatment.
Among the New Jersey hospitals included in the report, Saint Barnabas Medical Center in Livingston stands out as the only hospital in the state–and one of only a few dozen in the nation–that has earned an A rating on every safety report card since 2012. Eight other New Jersey hospitals improved their safety grade since last year’s report, including St. Luke’s Warren Campus in Phillipsburg, which took its rating from a C to an A.
As chairman of Cambridge Therapeutics, John Klein leads a team focused on manufacturing high-quality, customer-friendly medical devices, including prescription dispensing modalities for a variety of medications. In addition to his endeavors with Cambridge Therapeutics, John Klein is a recipient of the Ellis Island Medal of Honor.
In 1997, the Ellis Island Honors Society selected Mr. Klein and other recipients as prominent individuals who represent the best values of the United States, highlighting the rich mosaic of backgrounds from which the country’s population today derives. The landmark for which the organization is named is a symbol of the contributions immigrants and their descendants have made to American life.
Ellis Island is a small land mass situated in Upper New York Bay between Manhattan and New Jersey. It takes its name from Samuel Ellis, the merchant who was its owner around the time of the American Revolution. Just after the turn of the 19th century, the federal government purchased the island from the state of New York for use as a fort.
The island would become the largest station through which new immigrants had to enter the country. From 1892 to 1924, about 12 million individuals passed through its precincts. After 1924, its part in the immigration story drew to a close, and it was incorporated into the Statue of Liberty National Monument in 1965. Almost a dozen years later, the National Park Service took over the site’s administration. In 1990, its restored structures opened as the Ellis Island Immigration Museum.
At Cambridge Therapeutics, based in Teaneck, New Jersey, chairman John Klein directs the work of teams dedicated to innovation in medical products and pharmaceutical packaging. In keeping with his professional focus on helping to deliver high-quality medical care, Cambridge Therapeutics founder John Klein additionally serves on the board of trustees of Hackensack Meridian Health Hospitals.
Affiliated with Hackensack University Medical Center, HMH has developed the Center for Discovery and Innovation, which works to take pioneering techniques in biomedicine and harness them as a means of improving outcomes for patients with debilitating or life-threatening diseases, and as a way to prevent major diseases entirely. The center’s founders believed that the technological innovations of the 21st century can and should inform medical treatment more thoroughly for the benefit of patients and communities.
The center makes use of advances in the fields of genetics and genomics, bioengineering, immunology, and cellular and stem-cell biology, particularly in the treatment of cancer. The regenerative medical programs at the center also aim to discover the best ways of restoring tissues or entire organs damaged through injury or disease.
Among the individual units of the center are the Institute for Cancer and Infectious Diseases, and another institute dedicated to exploring best treatments for multiple myeloma.
At Cambridge Therapeutics in Teaneck, New Jersey, Chairman John Klein and his company work to manufacture high-quality, high-adherence medication packaging and other medical products. In addition to his work at Cambridge Therapeutics, John Klein has given extensively of his time to a number of educational and healthcare-focused nonprofit organizations, and has served as a trustee and past president of the Dwight-Englewood School, one of New England’s premier private preparatory academies.
Also known as D-E, the school currently serves close to 1,000 students, offering a comprehensive, co-educational learning experience for preschool to high school students. The school is proud of its diversity, with students coming from more than 80 distinct regions in New York and New Jersey.
Like many of the nation’s elite schools, D-E maintains a strong focus on ethics, a course required for every student in 10th grade. Among the reasons for teaching ethics at this level are the opportunities it offers students to encounter opposing viewpoints, to learn to identify faulty logic and rhetoric, and to be future leaders in an increasingly complex world.
Students in this one-semester class learn to think critically about important philosophical issues through discussion, intense essay-writing, and readings of case studies. Associated electives offered at the advanced level include honors courses on ancient and modern philosophy, as well as bioethics.